145 related articles for article (PubMed ID: 23244181)
21. Detection of lung cancer in silicosis patients using a tumor-marker panel.
Schneider J
Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960
[TBL] [Abstract][Full Text] [Related]
22. Non small cell lung cancer within the small cell lung cancer radiotherapy field after 11 years.
Munzuroglu F; Erturan S; Oz B; Dincbas FO; Demir G
J BUON; 2009; 14(2):313-6. PubMed ID: 19650185
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical and pathological tumor, node and metastasis staging of lung cancer: 15-year experience with 530 patients.
Turk F; Gursoy S; Yaldiz S; Yuncu G; Yazgan S; Basok O
Minerva Chir; 2011 Dec; 66(6):509-16. PubMed ID: 22233657
[TBL] [Abstract][Full Text] [Related]
24. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition.
Ignatius Ou SH; Zell JA
J Thorac Oncol; 2009 Mar; 4(3):300-10. PubMed ID: 19156001
[TBL] [Abstract][Full Text] [Related]
25. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
[TBL] [Abstract][Full Text] [Related]
26. Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors.
Zheng G; Ettinger DS; Maleki Z
Acta Cytol; 2013; 57(3):281-90. PubMed ID: 23635388
[TBL] [Abstract][Full Text] [Related]
27. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.
Vallières E; Shepherd FA; Crowley J; Van Houtte P; Postmus PE; Carney D; Chansky K; Shaikh Z; Goldstraw P;
J Thorac Oncol; 2009 Sep; 4(9):1049-59. PubMed ID: 19652623
[TBL] [Abstract][Full Text] [Related]
28. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.
Chansky K; Sculier JP; Crowley JJ; Giroux D; Van Meerbeeck J; Goldstraw P;
J Thorac Oncol; 2009 Jul; 4(7):792-801. PubMed ID: 19458556
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic utility of PAX2 and PAX5 in distinguishing non-small cell lung cancer from small cell lung cancer.
Ren Y; Hou J; Xu A; Pan Y
Int J Clin Exp Pathol; 2015; 8(11):14709-16. PubMed ID: 26823795
[TBL] [Abstract][Full Text] [Related]
30. [Exfoliative cytological diagnosis of lung cancer with bronchoscopic material].
Bolgova LS; Gordienko TM; Mantsurov NE; Krakhmalev SN; Koval'chuk EN
Klin Lab Diagn; 2009 Mar; (3):15-7. PubMed ID: 19391240
[TBL] [Abstract][Full Text] [Related]
31. TNM Staging of Non-Small Cell Lung Cancer: Comparison of PET/MR and PET/CT.
Huellner MW; de Galiza Barbosa F; Husmann L; Pietsch CM; Mader CE; Burger IA; Stolzmann P; Delso G; Frauenfelder T; von Schulthess GK; Veit-Haibach P
J Nucl Med; 2016 Jan; 57(1):21-6. PubMed ID: 26471696
[TBL] [Abstract][Full Text] [Related]
32. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
33. Imaging of the patient with non-small cell lung cancer.
Munden RF; Swisher SS; Stevens CW; Stewart DJ
Radiology; 2005 Dec; 237(3):803-18. PubMed ID: 16251391
[TBL] [Abstract][Full Text] [Related]
34. Identification of Gene Biomarkers for Distinguishing Small-Cell Lung Cancer from Non-Small-Cell Lung Cancer Using a Network-Based Approach.
Long F; Su JH; Liang B; Su LL; Jiang SJ
Biomed Res Int; 2015; 2015():685303. PubMed ID: 26290870
[TBL] [Abstract][Full Text] [Related]
35. Lung Cancer.
Lareau S; Slatore C; Smyth R
Am J Respir Crit Care Med; 2021 Dec; 204(12):P21-P22. PubMed ID: 34908517
[No Abstract] [Full Text] [Related]
36. [Recommendations for surgical treatment of nonsmall cell lung cancer].
Cordoş I; Bolca C; Paleru C
Pneumologia; 2009; 58(2):135-40. PubMed ID: 19637769
[TBL] [Abstract][Full Text] [Related]
37. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
38. EGFR mutation testing in non-small cell lung cancer (NSCLC).
Al Dayel F
J Infect Public Health; 2012 Dec; 5 Suppl 1():S31-4. PubMed ID: 23244184
[TBL] [Abstract][Full Text] [Related]
39. Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.
Takakuwa O; Maeno K; Kunii E; Ozasa H; Hijikata H; Uemura T; Kasai D; Ohkubo H; Miyazaki M; Oguri T; Niimi A
Lung Cancer; 2013 Aug; 81(2):174-9. PubMed ID: 23706418
[TBL] [Abstract][Full Text] [Related]
40. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
